Skip to main content
SpringerLink
Log in

Evidence for frequent reactivation of the Oka varicella vaccine strain in healthy vaccinees

  • Conference paper
Immunity to and Prevention of Herpes Zoster

  • 140 Accesses

Summary

Serum antibody levels and infection rates were followed for 4 years in 4,631 children immunized with the recently licensed Oka strain varicella vaccine. Anti-VZV titers declined over time in high-responder subjects, but rose in vaccinees with low titers. Among subjects with low anti-VZV titers, the frequency of clinical sequelae and immunological boosting significantly exceeded the 13%/yr rate of exposure to wild type varicella. These findings indicate that the Oka strain of VZV persisted in vivo, and reactivated as serum antibody titers declined after vaccination. This mechanism may improve vaccine-associated long-term immunity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arvin A, Koropchak C, Wittek A (1983) Immunologic evidence of re-infection with varicella-zoster virus. J Infect Dis 148: 200–205

    Article  PubMed  CAS  Google Scholar 

  2. Asano Y, Suga S, Yoshikawa T, Kobayashi I, Tazaki T, Shibata M, Tsuzuki K, Ito S (1994) Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94: 524–526

    PubMed  CAS  Google Scholar 

  3. Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, Chartrand SA, Cho I, Ngai A, White CJ (1993) Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 92: 833–837

    PubMed  CAS  Google Scholar 

  4. Brunell PA, Argaw T (2000) Chickenpox due to vaccine virus contracted from a vaccinee with zoster. Pediatrics 106: E28

    Article  PubMed  CAS  Google Scholar 

  5. Brunell PA, Taylor J, Geiser CF, Frierson L, Lydick E (1986) Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 77: 53–65

    PubMed  CAS  Google Scholar 

  6. Choo PW, Donahue JG, Manson JE, Platt R (1995) The epidemiology of varicella and its complications. J Infect Dis 172: 706–712

    Article  PubMed  CAS  Google Scholar 

  7. Cohen JI, Brunell PA, Straus SE, Krause PR (1999) NIH conference: recent advances in varicella-zoster virus infection. Ann Intern Med 130: 922–932

    PubMed  CAS  Google Scholar 

  8. Colton T (1974) Statistics in medicine. Little, Brown & Co., Boston

    Google Scholar 

  9. Finger R, Hughes J, Meade B, Pelletier A, Palmer C (1994) Age-specific incidence of chickenpox. Pub Health Rep 109: 750–755

    CAS  Google Scholar 

  10. Hardy I, Gershon AA, Steinberg SP, LaRussa P (1991) The incidence of zoster after immunization with live attenuated varicella vaccine. N Engl J Med 325: 1545–1550

    Article  PubMed  CAS  Google Scholar 

  11. Hope-Simpson RE (1965) The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc London 58: 9–20

    CAS  Google Scholar 

  12. Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML (1997) A long-term prospective study of varicella vaccine in healthy children. Pediatric 100: 761–766

    Article  CAS  Google Scholar 

  13. Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW (1986) Purification of individual varicella-zoster virus (VZV) glycoproteins gpl, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods 14: 177–188

    Article  PubMed  CAS  Google Scholar 

  14. Krause PR, Klinman DM (1995) Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatrics 127: 518–525

    Article  CAS  Google Scholar 

  15. Krause PR, Klinman DM (2000) Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nature Med 6: 451–454

    Article  PubMed  CAS  Google Scholar 

  16. Kuter B, Weibel R, Guess H, Mattthews H, Morton D, Neff B, Provost P, Watson B, Starr S, Plotkin S (1991) Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9: 643–647

    Article  PubMed  CAS  Google Scholar 

  17. Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist V, Wahren B (1986) Clinical and subclinical reactivation of varicella-zoster virus in immunocompromised patients. J Infect Dis 153: 840–847

    Article  PubMed  CAS  Google Scholar 

  18. Luby J, Ramirez-Ronda C, Rinner S, Hull A, Vergne-Marini P (1977) A longitudinal study of varicella-zoster virus infections in renal transplant recipients. J Infect Dis 135: 659–663

    Article  PubMed  CAS  Google Scholar 

  19. Merck & Co. (1998) Varivax [varicella virus vaccine live (Oka/Merck)] package circular In: 52nd Physician’s desk reference. Medical Economics Co., Montvale, pp 1762–1765

    Google Scholar 

  20. Plotkin SA (1994) Vaccines for varicella-zoster virus and cytomegalovirus: Recent progress. Science 265: 1383–1385

    Article  PubMed  CAS  Google Scholar 

  21. Scheiermann N, Gesemann M (1993) Anti-HBs antibody kinetics — A 4 year follow-up after hepatitis B vaccination. Zbl Bakt 278: 120–126

    CAS  Google Scholar 

  22. Straus SE, Reinhold W, Smith HA, Ruyechan WT, Henderson DK, Blaese RM, Hay J (1984) Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N Engl J Med 311: 1362–1364

    Article  PubMed  CAS  Google Scholar 

  23. Tomita H, Tanaka M, Kukimoto N, Ikeda M (1988) An ELISA study on varicella-zoster virus infection in acute peripheral facial palsy. Acta Otolaryngol (Stockh) [Suppl] 446: 10–16

    CAS  Google Scholar 

  24. Varis T, Vesikari T (1996) Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis [Suppl 3] 174: S330–334

    Article  Google Scholar 

  25. Wasmuth EH, Miller WJ (1990) Sensitive ELISA for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 32: 189–193

    Article  PubMed  CAS  Google Scholar 

  26. Watson BA, Starr SE (1994) Commentary: varicella vaccine for healthy children. Lancet 343: 928–929

    Article  PubMed  CAS  Google Scholar 

  27. Weibel RE, J NB, Kuter BJ (1984) Live attenuated varicella vaccine: efficacy trial in healthy children. N Engl J Med 310: 1409–1415

    Article  PubMed  CAS  Google Scholar 

  28. Wharton M (1996) The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 10: 571–581

    Article  PubMed  CAS  Google Scholar 

  29. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM (1992) Subclinical varicellazoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165: 119–126

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, CBER/FDA, Bldg 29A Rm 1 C 16, Bethesda, MD, 20892, USA

    P. R. Krause

  2. Division of Viral Products, CBER/FDA, Bldg 29A Rm 1 C 16, Bethesda, MD, 20892, USA

    P. R. Krause

Authors
  1. P. R. Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, College of Physicians & Surgeons, Columbia University, New York, USA

    Anne A. Gershon

  2. Department of Microbiology and Immunology, Stanford University, Stanford, USA

    Ann M. Arvin

  3. Arthropod-borne and Infectious Diseases Laboratory, Colorado State University, Fort Collins, USA

    Charles H. Calisher

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Wien

About this paper

Cite this paper

Krause, P.R. (2001). Evidence for frequent reactivation of the Oka varicella vaccine strain in healthy vaccinees. In: Gershon, A.A., Arvin, A.M., Calisher, C.H. (eds) Immunity to and Prevention of Herpes Zoster. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6259-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6259-0_2

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83555-5

  • Online ISBN: 978-3-7091-6259-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation